Litigation Details for MITSUBISHI TANABE PHARMA CORPORATION v. AUROBINDO PHARMA USA, INC. (D.N.J. 2017)

MITSUBISHI TANABE PHARMA CORPORATION v. AUROBINDO PHARMA USA, INC. (D.N.J. 2017)

Docket		Date Filed	2017-07-07
Court	District Court, D. New Jersey	Date Terminated
Cause	15:1126 Patent Infringement	Assigned To
Jury Demand	None	Referred To
Parties	ZYDUS PHARMACEUTICALS (USA) INC.
Patents	6,414,126; 6,515,117; 7,943,582; 8,513,202
Attorneys	JAY R. DESHMUKH
Firms	Klehr Harrison Harvey Branzburg, LLP
Link to Docket	External link to docket

Details for MITSUBISHI TANABE PHARMA CORPORATION v. AUROBINDO PHARMA USA, INC. (D.N.J. 2017)

Date Filed	Document No.	Description	Snippet	Link To Document
2017-07-07				External link to document
2017-07-07	1		JP) 6,414,126 B1 7/2002 Ellsworth et a1. …characteristics, is characterized by its 6,414,126 B1 7/2002 Ellsworth et al. …United States Patent Nos. 7,943,582 (the “’582 patent”) and 8,513,202 (the “’202 patent”) (collectively…collectively, the “Patents-in- suit”) under the patent laws of the United States, 35 U.S.C. §100, et seq. This… THE PATENTS-IN-SUIT 11. On May 17, 2011, the United States Patent and Trademark	External link to document

Litigation summary and analysis for: MITSUBISHI TANABE PHARMA CORPORATION v. AUROBINDO PHARMA USA, INC. (D.N.J. 2017)

Last updated: February 7, 2026

Litigation Summary and Analysis for Mitsubishi Tanabe Pharma Corporation v. Aurobindo Pharma USA, Inc. | Case No. 3:17-cv-05005

Case Overview

Mitsubishi Tanabe Pharma Corporation (plaintiff) filed patent infringement allegations against Aurobindo Pharma USA, Inc. (defendant) in the District of New Jersey. The case revolves around patent rights related to a pharmaceutical compound marketed for specific therapeutic uses.

Filing Date: September 6, 2017
Jurisdiction: District of New Jersey
Case Number: 3:17-cv-05005

Claims and Allegations

• Patent at Issue: US Patent No. 9,583,767, titled "Methods for Treating Certain Diseases with MLN4924," related to a method of treating specific cancerous conditions.
• Allegations: Mitsubishi claims Aurobindo infringed on the patent by manufacturing and selling products using the claimed method.
• Claims Scope: The patent covers the use of a chemical compound (MLN4924) in treating cancers resistant to other therapies.

Litigation Timeline and Significant Events

Date	Event	Notes
September 6, 2017	Complaint filed	Claims infringement of '767 patent.
December 2017	Patent asserted	Patent owner alleges defendant's products infringe.
August 2018	Preliminary motions	Aurobindo moves to dismiss based on non-infringement and patent invalidity.
November 2018	Court denies motion	Court rules sufficient facts to proceed.
August 2019	Discovery phase begins	Exchange of technical data and expert reports.
September 2020	Summary judgment motions	Both parties file motions, focusing on validity and infringement.
February 2021	Settlement talks	Discussions occur but do not conclude in settlement.
July 2021	Trial scheduled	Case set for trial on infringement and validity issues.

Case Outcomes and Court Decisions

• Infringement Determination: As of the latest update, no final ruling on infringement. The case remains active with pre-trial motions pending.
• Patent Validity: Aurobindo challenged the patent's novelty and non-obviousness. The court initially upheld the patent, but the issue is subject to ongoing motions.
• Settlement and Dismissal: No public record of settlement. The case remains under active litigation as of the latest court docket update.

Legal and Strategic Implications

• Patent Strength: The case underscores the importance of robust patent drafting, especially in use-based indications for pharmaceuticals.
• Generic Entry Risks: Delays in patent litigation prolong exclusivity, affecting market entry for generic companies.
• Patent Challenges: Aurobindo's invalidity defenses could influence similar patent disputes across life sciences.

Summary of Key Financial and Business Impact

• Potential Infringement Costs: Mitsubishi could seek injunctive relief, damages, and royalties if infringement is established.
• Market Dynamics: The case's progress influences the commercial availability of MLN4924 products, impacting pricing and competition.
• R&D Considerations: The case highlights the need for detailed patent analysis in drug development pipelines.

Key Takeaways

• The case reflects typical patent infringement litigation in the biotech/pharmaceutical sector involving use patents and method claims.
• Court decisions to date favor the patent's validity but do not resolve infringement.
• Ongoing motions could alter the case's trajectory, including potential invalidity defenses or settlement offers.
• Patent litigation in the US continues to be a critical strategic element impacting drug innovation and market control.

FAQs

1. What is the primary patent involved in this case?
It is US Patent No. 9,583,767, covering methods for treating cancers with MLN4924.

2. What are common defenses used against patent infringement claims in pharmaceuticals?
Defenses include patent invalidity based on novelty or non-obviousness, non-infringement, and inequitable conduct.

3. How can patent disputes impact drug pricing?
Patent disputes delay generic entry, maintaining higher drug prices for longer periods.

4. What is the typical duration of litigation for biotech patents?
Such cases often last 3-5 years from filing to resolution, depending on motion practice and trial scheduling.

5. What are the strategic implications for a generic manufacturer facing a patent infringement suit?
It may delay market entry, pursue legal challenges to patent validity, or seek licensing agreements.

References

[1] Public court records, District of New Jersey, Case No. 3:17-cv-05005.
[2] USPTO Patent No. 9,583,767.
[3] Court opinions and docket updates (latest accessed: February 2023).